Drug development is a tough business. Here's a closer look at seven of the biggest biotech flops of the year.
Shares collapsed after the company announced that it will discontinue development of some of its most promising product candidates.
The Soros Fund showed a healthy appetite for biotech stocks in Q3 -- ignoring the political risk.
Our team of healthcare experts thinks that these three biotech stocks are great choices for beginners.
Arrowhead's stock cratered after the announcement of an FDA clinical hold. Can the biotech make a comeback?
An attractively high dividend rate may have AbbVie on income investors' radar, but there are a few things investors should know about this company before they dive in and buy the stock for its dividend payout.
In anticipation of what proved to be disappointing third-quarter financial results, investors reduced their positions in the big-cap biotech stock.
Gilead Sciences is shifting its R&D budget away from the development of additional hepatitis C drugs.
Here's what you need to know about what Amgen's management said in the biotech's Q3 earnings call.
Cancer drug development is costly and fraught with failure, but these three companies have successfully navigated clinical trials and as a result, each has a chance at winning FDA approval of their drugs in 2017.